首页> 中文期刊> 《中华眼外伤职业眼病杂志 》 >贝伐单抗辅助玻璃体切除治疗增生性糖尿病视网膜病变的观察

贝伐单抗辅助玻璃体切除治疗增生性糖尿病视网膜病变的观察

摘要

Objective To evaluate the cinical efficacy of intravitreal Bevacizumab ( IVB) injection combined with 23-gauge pars plana vitrectomy ( PPV ) for proliferative diabetic retinopathy ( PDR ) . Methods This is a prospective study. Sixty eyes of sixty patients with PDR were randomly divided into two groups,research group and control group. Thirty eyes in research group were treated with 1. 25 mg IVB intravitreal injection 5-7 days before PPV , and another 30 eyes in control group underwent PPV without IVB treatment. The operation time, intraocular pressure ( IOP) , macular thickness, best corrected visual acuity ( BCVA) and complications were observed. Results Compared with control group, the operation time and the incidence of iatrogenic retinal breaks were significantly decreased, and silicon oil tamponade incidence decreased obviously in research group. The BCVA of research group was significantly better than that of control group(P<0. 05). There were no statistically significant differences between two groups in IOP and macular thickness. Conclusion IVB injection before PPV is helpful in reducing the operation time and incidence of iatrogenic retinal breaks, with improving the postoperative BCVA.%目的:评价术前贝伐单抗( Bevacizumab)玻璃体内注射联合23 G经睫状体平坦部玻璃体切除术( PPV)治疗增生性糖尿病性视网膜病变( PDR)的临床效果。方法本研究为前瞻性研究。PDR 60例(60)眼随机分为两组,30眼PPV术前5~7 d贝伐单抗1.25 mg玻璃体体内注射为研究组;另30眼PPV术前玻璃体内未注药为对照组。主要比较两组的手术时间、眼压、黄斑厚度、视力和并发症。结果与对照组相比,研究组的手术时间明显缩短,医源性视网膜损伤的发生率明显降低,硅油注入明显减少,术后视力显著提高更明显(P<0.05);两组间眼压和黄斑厚度的差异无统计学意义。结论 PPV术前辅助应用贝伐单抗玻璃体内注射可以缩短手术时间,减少术中医源性视网膜损伤的发生率,提高了手术安全性和术后视力。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号